Nabriva Therapeutics Plc (NBRV)

Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Theodore R. Schroeder
Employees:
70
56 FITZWILLIAM SQUARE, DUBLIN, IRELAND 2
(610) 816-6640

Nabriva Therapeutics plc engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI) XENLETA, a semi-synthetic pleuromutilin antibiotic, is in Phase I clinical trials for community-acquired bacterial pneumonia.

Data derived from most recent annual or quarterly report
Market Cap 4.933 Million Shares Outstanding3.064 Million Avg 30-day Volume 21.988 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-16.89
Price to Revenue0.1532 Debt to Equity-0.1244 EBITDA-52.015 Million
Price to Book Value0.0 Operating Margin-143.5612 Enterprise Value4.214 Million
Current Ratio0.846 EPS Growth0.16 Quick Ratio0.44
1 Yr BETA 0.632 52-week High/Low 8.45 / 1.22 Profit Margin-148.1057
Operating Cash Flow Growth50.8206 Altman Z-Score-43.7249 Free Cash Flow to Firm -12.169 Million
Earnings Report2023-08-03
View SEC Filings from NBRV instead.

View recent insider trading info

Nabriva Therapeutics Plc YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding NBRV (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding NBRV

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Ownership

  • 4: filed on 2023-01-10 by GELONE STEVEN P.
  • 4: filed on 2023-01-10 by SCHROEDER THEODORE R
  • 4: filed on 2023-01-04 by SCHROEDER THEODORE R
  • 4: filed on 2023-01-04 by GELONE STEVEN P.
  • 4: filed on 2022-12-08 by GELONE STEVEN P.
  • 4: filed on 2022-12-08 by SCHROEDER THEODORE R
  • 4: filed on 2022-12-02 by GELONE STEVEN P.
  • 4: filed on 2022-12-02 by SCHROEDER THEODORE R
  • 4: filed on 2022-11-08 by GELONE STEVEN P.
  • 4: filed on 2022-11-08 by SCHROEDER THEODORE R

    • Events (8k)

  • 8-K: filed on 2023-02-06:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-01-20:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-01-09:
    Item 1.02: Termination of a Material Definitive Agreement
    Item 2.05: Cost Associated with Exit or Disposal Activities
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-11-28:
    Item 8.01: Other Events
  • 8-K: filed on 2022-11-10:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-10-04:
    Item 8.01: Other Events
  • 8-K: filed on 2022-09-16:
    Item 3.03: Material Modifications to Rights of Security Holders
    Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-08-17:
    Item 5.07: Submission of Matters to a Vote of Security Holders
  • 8-K: filed on 2022-08-11:
    Item 8.01: Other Events
  • 8-K: filed on 2022-08-03:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits

    • Proposed Sales (Form 144)

    Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    SCHROEDER THEODORE R

    • Director
    		 11,989 2023-01-29 17

    GELONE STEVEN P.

    • Director
    		 14,283 2023-01-29 17

    NAFTZGER J. CHRISTOPHER GENERAL COUNSEL AND CORP SEC

    • Officer
    		 94,800 2022-08-11 1

    DOLAN DANIEL CHIEF FINANCIAL OFFICER

    • Officer
    		 124,800 2022-08-11 1

    GUICO-PABIA CHRISTINE J. CHIEF MEDICAL OFFICER

    • Officer
    		 107,200 2022-08-11 1

    BURGESS DANIEL D

    • Director
    		 10,384 2022-08-02 1

    CORRIGAN MARK

    • Director
    		 7,203 2022-08-02 1

    BROOM COLIN MD

    • Director
    		 36,523 2022-08-02 1

    WEBSTER STEPHEN W

    • Director
    		 11,447 2022-08-02 1

    BOURDOW CARRIE L.

    • Director
    		 9,933 2022-08-01 1

    DALTON LISA

    • Director
    		 9,100 2022-07-31 1

    CROTTY ROBERT GEN COUNSEL & CORP SECRETARY

    • Officer
    		 41,194 2021-08-31 0

    ROWLAND CHARLES A JR

    • Director
    		 23,773 2021-08-02 0

    SENDER GARY CHIEF FINANCIAL OFFICER

    • Officer
    		 20,472 2021-02-28 0

    SCHRANZ JENNIFER CHIEF MEDICAL OFFICER

    • Officer
    		 39,125 2021-02-28 0

    LAVINO FRANCESCO MARIA CHIEF COMMERCIAL OFFICER

    • Officer
    		 185,393 2020-09-30 0

    TALBOT GEORGE HARRISON

    • Director
    		 65,140 2020-07-29 0

    VIVO CAPITAL VIII, LLC

    • 10% Owner
    		 4,074,190 2017-09-18 0

    HBM HEALTHCARE INVESTMENTS (CAYMAN) LTD.

    • 10% Owner
    		 No longer subject to file 2017-09-12 0

    KHUONG CHAU QUANG

    • Director
    • 10% Owner
    		 3,919,600 2017-06-23 0

    SELTZER ELYSE G. CHIEF MEDICAL OFFICER

    • Officer
    		 2,400 2017-06-23 0

    ORBIMED ADVISORS LLC

    ORBIMED CAPITAL GP V LLC

    ISALY SAMUEL D

    • Director
    • 10% Owner
    		 391,960 2016-12-30 0

    WOLF JOHN PETER III GENERAL COUNSEL AND CORP. SEC.

    • Officer
    		 270 2016-12-30 0

    BOLTE AXEL

    • Director
    		 0 2016-12-30 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed    		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
    No current insider transactions

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    NABRIVA THERAPEUTICS PLC NBRV 2023-05-31 22:15:04 UTC -24.7245 29.7845 50000
    NABRIVA THERAPEUTICS PLC NBRV 2023-05-31 21:45:04 UTC -24.7245 29.7845 50000
    NABRIVA THERAPEUTICS PLC NBRV 2023-05-31 21:15:03 UTC -24.7245 29.7845 50000
    NABRIVA THERAPEUTICS PLC NBRV 2023-05-31 20:45:04 UTC -24.7245 29.7845 50000
    NABRIVA THERAPEUTICS PLC NBRV 2023-05-31 20:15:06 UTC -24.7245 29.7845 50000
    NABRIVA THERAPEUTICS PLC NBRV 2023-05-31 19:45:04 UTC -24.7245 29.7845 50000
    NABRIVA THERAPEUTICS PLC NBRV 2023-05-31 19:15:21 UTC -24.9415 30.0015 50000
    NABRIVA THERAPEUTICS PLC NBRV 2023-05-31 18:45:03 UTC -24.9415 30.0015 50000
    NABRIVA THERAPEUTICS PLC NBRV 2023-05-31 18:15:04 UTC -24.9415 30.0015 50000
    NABRIVA THERAPEUTICS PLC NBRV 2023-05-31 17:45:03 UTC -24.9415 30.0015 50000
    NABRIVA THERAPEUTICS PLC NBRV 2023-05-31 17:15:05 UTC -24.9415 30.0015 50000
    NABRIVA THERAPEUTICS PLC NBRV 2023-05-31 16:45:04 UTC -24.8492 29.9192 50000
    NABRIVA THERAPEUTICS PLC NBRV 2023-05-31 16:15:04 UTC -24.8492 29.9192 50000
    NABRIVA THERAPEUTICS PLC NBRV 2023-05-31 15:45:03 UTC -24.8492 29.9192 50000
    NABRIVA THERAPEUTICS PLC NBRV 2023-05-31 15:15:04 UTC -24.8492 29.9192 50000
    NABRIVA THERAPEUTICS PLC NBRV 2023-05-31 14:45:04 UTC -24.8492 29.9192 50000
    NABRIVA THERAPEUTICS PLC NBRV 2023-05-31 14:15:03 UTC -24.8492 29.9192 50000
    NABRIVA THERAPEUTICS PLC NBRV 2023-05-31 13:45:04 UTC -24.7832 29.8532 50000
    NABRIVA THERAPEUTICS PLC NBRV 2023-05-31 13:15:04 UTC -24.7832 29.8532 50000
    NABRIVA THERAPEUTICS PLC NBRV 2023-05-31 12:45:04 UTC -24.7832 29.8532 50000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    Elevate your investments